معرفی
Hassane M. Zarour is Professor of Medicine (Division of Hematology/Oncology), Immunology, and Dermatology at the University of Pittsburgh School of Medicine, holding the James W. and Frances G. McGlothlin Chair in Melanoma Immunotherapy Research and co-leading UPMC Hillman Cancer Center's Melanoma Program.
His educational background includes:
- MD, Marseille School of Medicine (France), 1991
- Dermatology specialization, Marseille School of Medicine (France), 1991
- Residency in Dermatology, Marseille School of Medicine (France), 1991
- Fellowship in Tumor Immunology, Ludwig Institute for Cancer Research, Brussels, 1995
Dr. Zarour's research pioneers melanoma immunotherapy through identification of MHC class II tumor epitopes (NY-ESO-1/LAGE-1), analysis of CD4+/CD8+ T-cell responses, and dissection of immune checkpoint pathways (PD-1, Tim-3, BTLA, TIGIT). His work extends to gut microbiome modulation of checkpoint blockade responses and development of peptide/protein-based vaccines with CpG adjuvants.
Analysis of his 2000-2016 publications reveals dominant themes in T-cell dysfunction mechanisms and combinatorial immunotherapy approaches, with increasing focus on multi-checkpoint inhibition (PD-1/Tim-3/TIGIT) and microbiome interactions in later work.
His scientific recognition includes:
- Training Grant, Association pour la Recherche sur le Cancer, France (1993-1994)
Dr. Zarour mentors pre/postdoctoral fellows, oncology trainees, and junior faculty while co-directing the Cancer Immunotherapy Trial Network. He organizes monthly Melanoma Program seminars to foster collaborations and serves on NIH review panels and UPMC's Protocol Review Committee.
His laboratory operates within Hillman Cancer Center's Melanoma Program, collaborating with the Cancer Vaccine Collaborative Group and conducting clinical trials including fecal microbiota transplants for PD-1 refractory melanoma.
